Mirtazapine improves visual hallucinations in Parkinson's disease: a case report

@article{Tagai2013MirtazapineIV,
  title={Mirtazapine improves visual hallucinations in Parkinson's disease: a case report},
  author={K. Tagai and T. Nagata and Shunichiro Shinagawa and N. Tsuno and M. Ozone and K. Nakayama},
  journal={Psychogeriatrics},
  year={2013},
  volume={13}
}
Psychotic symptoms often occur as a complication in Parkinson's disease patients, and a set of criteria for Parkinson's disease with psychosis (PDPsy) has been established. Among these criteria, hallucinations are one of the specific symptoms, with visual hallucinations being the most common. While atypical antipsychotic agents are often used for the treatment of PDPsy, adverse effects, including extrapyramidal symptoms, often hinder its continuation or tolerance. There have been some reports… Expand
A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease
TLDR
The present case suggests the effectiveness of MRZ for the treatment of refractory AHs in patients with PD, and a new-generation antidepressant, mirtazapine (MRZ), was commenced. Expand
Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report
TLDR
A 75-year-old female patient with PD who visited the clinic with complaints of recurrent visual hallucinations and cognitive decline, whose symptoms were ameliorated by the titration of rivastigmine is reported, suggesting that pronounced amyloid deposition and visual hallucinations in PD patients could be clinically significant predictors of cognitive decline inPD patients. Expand
Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management
TLDR
Treatment of PD psychosis requires a step-wise process, including initial careful investigation of treatable triggering conditions and a comprehensive evaluation with adjustment of PD medications and/or initiation of specific antipsychotic therapies. Expand
Visual hallucinations in Parkinson's disease: Theoretical models
TLDR
This review considers the leading hypothetical frameworks for visual hallucinations in Parkinson's disease, summarizing the key aspects of each in an attempt to highlight the aspects of the condition that such a unifying hypothesis must explain. Expand
Hallucinations and the spectrum of psychosis in Parkinson's disease
TLDR
The various types of hallucinations and psychotic symptoms comprising the spectrum of Parkinson's disease psychosis is the subject of this review article. Expand
Therapies under investigation for treating Parkinson's disease psychosis
TLDR
Some of the available therapies to treat PD psychosis are discussed and drugs that have recently undergone investigation, or are presently being studied to address this condition are surveyed. Expand
Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series
TLDR
The conclusions that can be drawn on the efficacy of antidepressants at reducing PD psychosis are limited because of the poor quality of the reported studies, but it is encouraging to notice that there are positive anecdotal reports. Expand
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset
TLDR
The results suggest that mirtazapine may be effective to alleviate PD psychosis and, because the drug is clinically available, clinical trials that would assess its anti-psychotic efficacy in PD could be rapidly undertaken, hopefully leading to a new treatment option for this debilitating condition. Expand
Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics.
TLDR
The National Institutes of Mental Health Research Domain Criteria (RDoC) is utilized to frame and integrate observations from two prevailing disease constructions: neurotransmitter anomalies and circuit physiology. Expand
The Pharmacology of Visual Hallucinations in Synucleinopathies
TLDR
The review analyzes the past and recent hypotheses that are related to the underlying mechanisms of VH and offers an up to date analysis of treatment options. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 38 REFERENCES
Parkinson's disease psychosis 2010: a review article.
  • J. Friedman
  • Psychology, Medicine
  • Parkinsonism & related disorders
  • 2010
TLDR
Treatment of Parkinson's disease psychosis (PDP) focuses on reducing the psychiatric symptom load while balancing the competing problem of mobility, using either acetylcholinesterase inhibitors or atypical anti-psychotics. Expand
Psychotic symptoms in Parkinson's disease. From description to etiology.
TLDR
Evidence is reviewed that links ventral dopaminergic pathway dysfunction (overactivity) together with the involvement of other neurotransmitter system imbalances as likely contributors to psychosis in Parkinson's disease, and a proposed mechanism is proposed that successful management of psychotic symptoms in PD may rely on a multitarget approach. Expand
Hallucinations and psychosis in Parkinson's disease.
  • J. Rabey
  • Psychology, Medicine
  • Parkinsonism & related disorders
  • 2009
TLDR
Accumulated clinical data have shown that "minor symptoms" and benign hallucinations also imply a bad prognosis with time, and from an operational point of view there remain difficulties in defining a specific time of exposure and dose of treatment and the occurrence of PDPsy. Expand
Management of hallucinations and psychosis in Parkinson's disease.
  • M. Eng, T. Welty
  • Medicine
  • The American journal of geriatric pharmacotherapy
  • 2010
TLDR
Results of the identified studies suggested that patients with PD might benefit from long-term clozapine therapy, while results of the quetiapine studies were conflicting and the significance of the differences in treatment responses between patients with dementia and those without dementia remains unclear. Expand
Pathophysiology and Treatment of Psychosis in Parkinson’s Disease
TLDR
Case reports suggest that electroconvulsive therapy has the potential to reduce psychotic symptoms and may be considered in cases involving concurrent depression and/or medication-refractory psychosis, and case reports also suggest that specific antidepressants may improve psychosis in depressed patients. Expand
Psychosis in Parkinson's Disease: Phenomenology, Frequency, Risk Factors, and Current Understanding of Pathophysiologic Mechanisms
TLDR
Hallucinations may involve several sensory modalities and include visual illusions, passage hallucinations, and sense of presence in Parkinson's disease patients with cognitive impairment. Expand
Psychosis in advanced Parkinson's disease
TLDR
It is suggested that pharmacologic blockade of central 5-HT receptors may become a strategy to attenuate PD psychosis without inducing motor deterioration or suppression of antiparkinsonian action of levodopa, and it lends support to the hypothesis that serotonergic mechanisms are pathogenetically important in the emergence of psychosis in PD. Expand
Visual hallucinations associated with Parkinson disease.
TLDR
While reduction in levodopa and anticholinergic medication doses is appropriate in the management of hallucinations, the factors that predispose patients to hallucinations include dementia and advancing age. Expand
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
TLDR
Findings indicate that, when minor hallucinations are included, the total prevalence of hallucinations in Parkinson's disease is much higher than previously reported, and a simple side-effect of dopaminergic treatment is not sufficient to explain the occurrence of all visual hallucinations. Expand
Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease.
TLDR
A patient with Parkinson disease with psychotic symptoms and comorbid depression whose treatment refractory delusions and hallucinations improved markedly only after antidepressant monotherapy was initiated is described. Expand
...
1
2
3
4
...